1,445,700Accrued expenses and other liabilities2,850,0723,169,642Current portion of long term debt195,412-Short term debt857,808-Total current liabilities5,313,8084,615,342Other long term liabilities555,983449,709Long term debt, less current portion2,234,712-Derivative instruments2,878,3141,886,652Total liabilities10,982,8176,951,703Stockholders' equity:Common stock, $0.0001 par value; 100,000,000 shares authorized;
48,314,510 and 48,236,172 shares issued and outstanding at March 31, 2012
and December 31, 2011, respectively4,8324,824Additional paid-in-capital209,111,489208,525,917Accumulated other comprehensive income1,023,8911,010,522Accumulated deficit(196,369,345)(193,689,457)Total stockholders'
equity13,770,86715,851,806Total liabilities and stockholders' equity$
22,803,509 PHARMATHENE, INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONSThree months ended March 31,20122011Revenue
6,337,722Operating expenses:Research and development4,705,3575,820,374General and administrative2,948,4814,939,654Depreciation and amortization85,910117,629Total operating expenses7,739,74810,877,657Loss from operations(1,590,696)(4,539,935)Other income (expense):Interest income2,9883,154Interest expense(3,028)(15,435)Other income (expense)52,915(11,906)Change in fair value of derivative instruments(991,662)2,488,465Total other income (expense)(938,787)2,464,278Net loss before income taxes(2,529,483)(2,075,657) Income tax expense(150,405)- Net loss
(2,075,657)Basic and diluted net loss per share
(0.04)Weighted average shares used in calculation of
basic and diluted net loss per share48,269,89446,276,874
|SOURCE PharmAthene, Inc.|
Copyright©2010 PR Newswire.
All rights reserved